Research programme: uPAR antagonists - Angstrom
Alternative Names: A 36Latest Information Update: 21 Nov 2021
At a glance
- Originator Angstrom Pharmaceuticals
- Class Peptides; Small molecules
- Mechanism of Action Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration
- Discontinued Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intraocular, Implant)
- 23 Aug 2012 Preclinical development is ongoing in USA
- 19 Jul 2012 Discontinued - Preclinical for Cancer in USA (unspecified route)